Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review) - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review) - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
复制标题
DOI：
10.1212/01.wnl.0000311391.00944.c4
复制
发表时间：
2008-05-06
期刊：
影响因子：
9.9
通讯作者：
So, Y.
中科院分区：
文献类型：
--
作者：
Simpson, D. M.;Gracies, J. -M.;So, Y.
目的：进行循证审查肉毒神经毒素（BoNT）在成人和儿童spasticity.Methods治疗的安全性和有效性：进行了文献检索，包括MEDLINE和当前内容的治疗文章相关BoNT和痉挛。作者根据美国神经病学学会标准对文章进行了综述、摘要和分类结果：针对相应适应症的最高质量文献如下：成人痉挛（14项I类研究）;小儿脑瘫中的马蹄痉挛和内收肌痉挛建议：肉毒神经毒素应作为治疗成人和儿童痉挛的一种治疗选择（A级）。
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of adult and childhood spasticity.Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and spasticity. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (ClassI-IV).Results: The highest quality literature available for the respective indications was as follows: adult spasticity (14 Class I studies); spastic equinus and adductor spasticity in pediatric cerebral palsy (six Class I studies).Recommendations: Botulinum neurotoxin should be offered as a treatment option for the treatment of spasticity in adults and children (Level A).